SEC Form 3: New insider Pillar Invest Corp claimed ownership of 663,046 shares
$IDRA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 05/16/2023 |
3. Issuer Name and Ticker or Trading Symbol
Aceragen, Inc. [ ACGN ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 355,247 | I | By Pillar Partners Foundation, L.P.(1) |
| Common Stock | 135,540 | I | By Pillar Pharmaceuticals 6, L.P(1) |
| Common Stock | 170,712 | I | By Abude Umari(1) |
| Common Stock | 1,547 | I | By Youssef El Zein(1) |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Warrants | 07/13/2020 | 07/13/2023 | Common Stock | 162,601(2) | 0.01 | I | By Pillar Partners Foundation, L.P.(1) |
| Warrants | 12/11/2020 | 12/11/2023 | Common Stock | 35,687(2) | 0.01 | I | By Pillar Partners Foundation, L.P.(1) |
| Warrants | 12/11/2020 | 12/11/2023 | Common Stock | 45,114(2) | 0.01 | I | By Pillar Pharmaceuticals 6, L.P.(1) |
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
| Explanation of Responses: |
| 1. Pillar Invest Corporation ("Pillar GP") is the general partner of Pillar Pharmaceuticals 6, L.P. ("Pillar 6") and Pillar Partners Foundation, L.P. ("Pillar Partners", together with Pillar GP and Pillar 6, the "Pillar Funds"). Youssef El Zein and Abude Umari are directors of Pillar GP. Each of Pillar GP, Mr. El Zein and Mr. Umari disclaims Section 16 beneficial ownership of the securities beneficially owned by the Pillar Funds and this report shall not be deemed an admission that any of Pillar GP, Mr. El Zein or Mr. Umari is the Section 16 beneficial owner of any such securities, except to the extent of its or his pecuniary interest therein, if any, by virtue of its or his ownership interest in the Pillar Funds or Pillar GP, as applicable. |
| 2. The warrants are exercisable subject to a beneficial ownership blocker provision that prevents the holder from exercising the warrants if such exercise would result in the holder beneficially owning more than 19.99% of the Issuer's Common Stock outstanding following such exercise. |
| Remarks: |
| Pillar Invest Corporation, /s/ Youssef El Zein, Authorized Person | 06/23/2023 | |
| Pillar Partners Foundation, L.P., /s/ Youssef El Zein, Authorized Person | 06/23/2023 | |
| Pillar Pharmaceuticals, 6, L.P., /s/ Youssef El Zein, Authorized Person | 06/23/2023 | |
| /s/ Abude Umari | 06/23/2023 | |
| /s/ Youssef El Zein | 06/23/2023 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||